Physician profile
Daniel J Abraham
NPI 1497709778
$1,008.72
in general payments reported to CMS, 2019-2025
14 companies · $629 in 2025
The $629 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72.30 · 2020: $36.07 · 2021: $13.88 · 2022: $38.70 · 2023: $101 · 2024: $117 · 2025: $629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $848.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $847.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $363.72 | 2019-2025 | Skyrizi |
| Janssen Biotech, INC. | $106.47 | 2023-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $101.31 | 2021-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $73.73 | 2023-2025 | Sotyktu |
| Ucb, INC. | $70.66 | 2024-2025 | Bimzelx |
| Organon LLC | $49.63 | 2025 | Vtama |
| Novartis Pharmaceuticals Corporation | $46.21 | 2024-2025 | |
| Genzyme Corporation | $42.28 | 2023-2025 | |
| Leo Pharma INC. | $38.37 | 2019-2025 | Anzupgo |
| Lilly USA, LLC | $34.90 | 2024-2025 | Taltz, Ebglyss, Olumiant |
| Galderma Laboratories, L.P. | $30.20 | 2025 | Nemluvio |
| Verrica Pharmaceuticals INC. | $19.38 | 2025 | Ycanth |
| Sun Pharmaceutical Industries INC. | $17.10 | 2022 | |
| Pfizer INC. | $14.76 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.